Literature DB >> 26140980

In vitro antitumor immune response induced by dendritic cells transduced with human livin α recombinant adenovirus.

Junping Xie1, Xiaolin Guo2, Fangfang Liu2, Junming Luo3, Fengying Duan3, Xiaonan Tao4.   

Abstract

Transduction with recombinant, replication-defective adenoviral (rAd) vectors encoding a transgene is an efficient method for gene transfer into human dendritic cells (DCs). Livin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues. Two splicing variants of livin, designated livin α and livin β, have been identified. In this study, we used human livin α recombinant adenovirus (rAd-hlivin α) to transduced DCs. We found that DCs transduced with rAd-hlivin α (rAd-hlivin α DCs) could effectively induce human livin α specific cytotoxic T lymphocytes (CTL) in vitro against various tumor cell lines.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dendritic cell; Gene therapy; Livin α; Recombinant adenoviral vector; Tumor cell

Mesh:

Substances:

Year:  2015        PMID: 26140980     DOI: 10.1016/j.cellimm.2015.06.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

Review 1.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

2.  Livin in synergy with Ras induces and sustains corticosteroid resistance in the airway mucosa.

Authors:  Jin-Mei Xue; Yun-Fang An; Li-Min Suo; Li-Hua Mo; Gui Yang; Xiang-Qian Luo; Da-Bo Liu; Chang-Qing Zhao; Ping-Chang Yang
Journal:  Int J Biol Sci       Date:  2021-05-13       Impact factor: 6.580

Review 3.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.